Sugi Predict

Sugi Predict / Compounds / SCHEMBL5286259

SCHEMBL5286259

SCHEMBL5286259

NC(Cc1ccc(N=Nc2ccccc2)cc1)C(=O)O

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC7A5 Q01650 4/20 0.70
▸ PTGS1 P23219 3/20 0.70
▸ ALPI P09923 1/20 0.70
▸ PKM P14618 1/20 0.70
▸ XIAP P98170 1/20 0.70
▸ TPH1 P17752 2/20 0.55
▸ NOS3 P29474 3/20 0.55
▸ NOS1 P29475 3/20 0.55
▸ NOS2 P35228 3/20 0.55
▸ ALOX15 P16050 3/20 0.51
▸ HIF1A Q16665 3/20 0.51
▸ KDM4E B2RXH2 2/20 0.51
▸ TDP1 Q9NUW8 2/20 0.51
▸ SLC1A3 P43003 1/20 0.51
▸ SLC1A2 P43004 1/20 0.51
▸ SLC1A1 P43005 1/20 0.51
▸ USP2 O75604 1/20 0.51
▸ EGFR P00533 1/20 0.51
▸ LCK P06239 1/20 0.51
▸ FYN P06241 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19368127 1.00 SLC7A5 (0.70) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL1712908 1.00 SLC7A5 (0.70) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL12272708 1.00 SLC7A5 (0.70) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL4338268 1.00 SLC7A5 (0.70) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL4285203 0.95 SLC7A5 (0.64) SLC7A5PTGS1ALPIPKMXIAP
Azobenzene SCHEMBL23038628 0.95 SLC7A5 (0.79) SLC7A5PTGS1ALPIPKMXIAP
Azobenzene SCHEMBL8497483 0.92 SLC7A5 (0.75) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL28349276 0.87 TPH1 (0.60) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL28349278 0.87 TPH1 (0.60) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL28366916 0.86 SLC7A5 (0.65) SLC7A5PTGS1ALPIPKMXIAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5658885-A OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1997-08-19 — — US claimed
CN-105263962-B Antibodies and methods for treating estrogen receptor-related diseases 北京盛诺基医药科技股份有限公司 2019-12-31 — — CN disclosed
CN-105263962-A Antibodies and methods for treating estrogen receptor-associated diseases BEIJING SHENOGEN PHARMACEUTICAL TECHNOLOGY CO LTD 2016-01-20 — — CN disclosed
WO-2007002469-A2 THERAPEUTIC COMPOSITIONS AND METHODS USING TRANSFORMING GROWTH FACTOR-BETA MIMICS BHATNAGAR RAJENDRA S (US) 2007-01-04 — — WO disclosed
WO-2007002594-A1 COSMETIC COMPOSITIONS AND METHODS USING TRANSFORMING GROWTH FACTOR-BETA MIMICS BHATNAGAR RAJENDRA S (US) 2007-01-04 — — WO disclosed
US-20060293227-A1 Cosmetic compositions and methods using transforming growth factor-beta mimics BHATNAGAR RAJENDRA S 2006-12-28 — — US disclosed
US-20060293228-A1 Therapeutic compositions and methods using transforming growth factor-beta mimics BHATNAGAR RAJENDRA S 2006-12-28 — — US disclosed
US-6939854-B2 Peptide inhibitors of hepatitis C virus NS3 protease BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2005-09-06 — — US disclosed
US-6846806-B2 Peptide inhibitors of Hepatitis C virus NS3 protein BRISTOL-MYERS SQUIBB COMPANY (US) 2005-01-25 — — US disclosed
US-6774212-B2 FOR THERAPY OF VIRAL INFECTION OR AS AN ASSAY STANDARD OR REAGENT BRISTOL-MYERS SQUIBB PHARMA COMPANY 2004-08-10 — — US disclosed
EP-1252178-A1 ALPHA-KETOAMIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE Bristol-Myers Squibb Pharma Company (US) 2002-10-30 — — EP disclosed
US-20020123468-A1 Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-09-05 — — US disclosed
US-20020065248-A1 Inhibitors of hepatitis C virus NS3 protease BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-05-30 — — US disclosed
EP-1196436-A2 PEPTIDE BORONIC ACID INHIBITORS OF HEPATITIS C VIRUS PROTEASE Bristol-Myers Squibb Pharma Company (US) 2002-04-17 — — EP disclosed
WO-2001064678-A2 INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2001-09-07 — — WO disclosed
WO-2001040262-A1 ALPHA-KETOAMIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2001-06-07 — — WO disclosed
WO-2001002424-A2 PEPTIDE BORONIC ACID INHIBITORS OF HEPATITIS C VIRUS PROTEASE DU PONT PHARMACEUTICALS COMPANY (US) 2001-01-11 — — WO disclosed
US-5658885-A OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1997-08-19 — — US disclosed
EP-0787010-A1 AMIDINO AND GUANIDINO SUBSTITUTED INHIBITORS OF TRYPSIN-LIKE ENZYMES THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1997-08-06 — — EP disclosed
WO-1996012499-A1 AMIDINO AND GUANIDINO SUBSTITUTED INHIBITORS OF TRYPSIN-LIKE ENZYMES THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1996-05-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020065248-A1 Inhibitors of hepatitis C virus NS3 protease TMPRSS15, CTRC, CPN1 SLC7A5 860/4885PTGS1 118/4885ALPI 1405/4885
US-20020123468-A1 Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease CES1, CYP51A1, SPINT2 SLC7A5 2566/4885PTGS1 433/4885ALPI 1246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.